Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Efficacy of primary prophylactic GCSF in patients receiving docetaxel based chemotherapy for breast cancer.

Sub-category:
Adjuvant Therapy

Category:
Breast Cancer—Local/Regional/Adjuvant

Meeting:
2018 ASCO Annual Meeting

Abstract No:
e12516

Citation:
J Clin Oncol 36, 2018 (suppl; abstr e12516)

Author(s): Jamal M Zekri, Azhar Nawaz, Haleem J. Rasool, Imran Ahmad, Hossam Abdel Rahman, Ahmed Allithy, Ehab Mosaad Abdelghany, Kamel Farag, Refaei Belal Ibrahim, Mohamed Youssef Deibas, Mohamed Kamal Kamel, Reyad Dada; Professor, Al-Faisal University, Consultant Oncologist, King Faisal Special Hospital & Research Centre, Jeddah, Saudi Arabia; King Faisal Specialist Hospital & Research Center-Jeddah Branch, Jeddah, Saudi Arabia; Mayo Clinic Health System, La Crosse, WI; King Faisal Specialist Hosp and Research Ctr, Al-Faisal University, Jeddah PO Box 40047, AR, Saudi Arabia; KFSHRCJ, Jeddah, Saudi Arabia; Assistant Consultant King Faisal Specialist Hospital & Research Center-Jeddah Branch, Jeddah, Saudi Arabia; King Faisal Specialist Hospital and Research Center, Cancer National Institute/Cairo University, Jeddah, Saudi Arabia; Assistant Professor of Medical Oncology, Faculty of Medicine Mansoura University, Egypt. Assistant Consultant Oncologist, King Faisal Special Hospital and Research Centre (Jeddah), Jeddah, Saudi Arabia; Clinical Oncology Department Al-Hussein University Hospital, Faculty of Medicine Al-Azhar University, Cairo, Egypt; Cairo University, MRCP Ireland, Cairo, Egypt; King Faisal Specialist Hospital and Research Center, Medical College, Al-Faisal University, Saudi Arabia, Jeddah, Saudi Arabia

Abstract Disclosures

Abstract:

Background: Primary prophylactic Granulocyte Colony Stimulating Factor (PP-GCSF) is recommended for patients receiving single agent docetaxel (SAD) and docetaxel combination regimens (DCR) to reduce risk of febrile neutropenia (FN). This study aims to investigate the benefit of PP-GCSF in these patients in real life daily setting. Methods: All consecutive patients (n = 276) with breast cancer who received SAD or DCR between years 2015 and 2017 were included. Starting dose of Docetaxel was 80 mg/m2 in SAD and was variable in different DCRs. Data was collected retrospectively. Chi-square and Mann–Whitney–Wilcoxon tests were used as appropriate to detect significance of differences. The outcome presented in this abstract is limited to findings related to 1st and 2nd cycles of chemotherapy. Results of comprehensive analyses will be presented at the conference. Results: Median age was 50 (21-75) years. Treatment intent was curative in 233 (84.4%) and palliative in 43 (15.6%) patients. 193 (69.9%) received PP-GCSF after first cycle of chemotherapy while 83 (30.1%) did not. FN was less frequent in patients who received SAD (P = 0.046) and in those who received primary PP-GCSF (P = 0.02) compared to DCR and no GCSF prophylaxis respectively (Table). There was a tendency to shorter admission days after FN (P = 0.098) and less cycle 2 chemotherapy dose reduction (P = 0.525) and delays (P = 0.256) in patients who received PP-GCSF compared to those who did not. Conclusions: PP-GCSF significantly reduces the risk of FN in patients receiving docetaxel based chemotherapy. It may also shorten duration of admission after 1st cycle of docetaxel based therapy and enables more optimal subsequent treatment delivery.

NumberRate of FN after 1st cycleMean duration (range) of admission for FN in daysCycle 2 dose reductionCycle 2 dose delay
All patients27625 (9.1%)4.56 (1-15)60/265 (22.6%)39/265 (14.7%)
SAD138/276 (50%)8/138 (5.8%)4 (1-6)29/131 (22.1%)19/131 (14.5%)
DCR138/276 (50%)17/138 (12.3%)4.82 (1-15)31/134 (23.1%)20/134 (14.9%)
Received PP-GCSF193 (69.9%)12/193 (6.2%)3.67 (1-7)40/185 (21.6%)24/184 (13%)
No PP-GCSF83 (30.1%)13/83 (15.7%)5.38 (1-15)20/80 (25%)15/79 (19%)

 
Other Abstracts in this Sub-Category:

 

1. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

Meeting: 2018 ASCO Annual Meeting Abstract No: LBA1 First Author: Joseph A. Sparano
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

2. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 500 First Author: Michael Gnant
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

3. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.

Meeting: 2018 ASCO Annual Meeting Abstract No: 501 First Author: Robert E. Coleman
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy

 

More...